ORGO · Organogenesis Holdings Inc. · Insider Trading

$0.82 +0.01 (+1.17%) Play latest call Q3 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$105.55M

129.80M

Volume · Nov 9 73.51K Avg daily vol (3M) 879.14K

Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.

Query insider transactions through the insider trading API or MCP →

Date	Insider	Role	Type	Security	Shares	Price	Value	After
2026-03-09	Driscoll Michael Joseph	Director	Buy↑	Class A Common Stock	10,000	$2.67	$26,688	225,707
2026-03-09	Leibowitz Arthur S	Director	Buy↑	Class A Common Stock	5,000	$2.68	$13,405	291,014
2026-03-01	Cavorsi Robert	Vice President, Strategy	Tax↓	Class A Common Stock	700	$3.21	$2,247	275,524
2026-02-18	Korfin Michele Ilene	Director	Award↑ Filing footnotes — Class A Common Stock (Direct) Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.	Class A Common Stock	48,828	—	—	239,073
2026-02-18	Cavorsi Robert	Vice President, Strategy	Tax↓ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	5,487	$3.84	$21,070	276,224
2026-02-18	Grow Brian	Chief Commercial Officer	Award↑ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	48,818	—	—	911,611
2026-02-18	Driscoll Michael Joseph	Director	Award↑ Filing footnotes — Class A Common Stock (Direct) Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.	Class A Common Stock	48,828	—	—	215,707
2026-02-18	Freedman Lori	Chief Admin. and Legal Officer	Tax↓ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	14,411	$3.84	$55,338	1,023,643
2026-02-18	Freedman Lori	Chief Admin. and Legal Officer	Award↑ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	43,212	—	—	1,038,054
2026-02-18	Quintero Gilberto	Director	Award↑ Filing footnotes — Class A Common Stock (Direct) Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.	Class A Common Stock	48,828	—	—	239,073
2026-02-18	Gillheeney Gary S.	Director, President and CEO	Award↑ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	188,856	—	—	4,323,398
2026-02-18	Cavorsi Robert	Vice President, Strategy	Award↑ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	16,454	—	—	281,711
2026-02-18	Bilbo Patrick	Chief Operating Officer	Award↑ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	49,102	—	—	1,144,687
2026-02-18	Leibowitz Arthur S	Director	Award↑ Filing footnotes — Class A Common Stock (Direct) Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.	Class A Common Stock	48,828	—	—	286,014
2026-02-18	Giacomin Jon L	Director	Award↑ Filing footnotes — Class A Common Stock (Direct) Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.	Class A Common Stock	48,828	—	—	241,026
2026-02-18	Francisco David	Chief Financial Officer	Tax↓ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	14,687	$3.84	$56,398	731,312
2026-02-18	Bilbo Patrick	Chief Operating Officer	Tax↓ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	16,375	$3.84	$62,880	1,128,312
2026-02-18	Montecalvo Antonio S.	Vice President, Health Policy	Tax↓ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	3,778	$3.84	$14,508	226,238
2026-02-18	Lustig Garrett	Director	Award↑ Filing footnotes — Class A Common Stock (Direct) Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.	Class A Common Stock	48,828	—	—	125,742
2026-02-18	Montecalvo Antonio S.	Vice President, Health Policy	Award↑ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	11,330	—	—	230,016
2026-02-18	Duraibabu Prathyusha	Director	Award↑ Filing footnotes — Class A Common Stock (Direct) Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.	Class A Common Stock	48,828	—	—	247,047
2026-02-18	Grow Brian	Chief Commercial Officer	Tax↓ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	11,887	$3.84	$45,646	899,724
2026-02-18	Francisco David	Chief Financial Officer	Award↑ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	44,040	—	—	745,999
2026-02-18	Gillheeney Gary S.	Director, President and CEO	Tax↓ Filing footnotes — Class A Common Stock (Direct) This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.	Class A Common Stock	91,311	$3.84	$350,634	4,232,087
2026-02-15	Bilbo Patrick	Chief Operating Officer	Tax↓	Class A Common Stock	15,617	$3.73	$58,251	900,000
2026-02-15	Gillheeney Gary S.	Director, President and CEO	Tax↓	Class A Common Stock	85,605	$3.73	$319,307	3,243,917
2026-02-15	Gillheeney Gary S.	Director, President and CEO	Tax↓	Class A Common Stock	82,815	$3.73	$308,900	3,329,522
2026-02-15	Montecalvo Antonio S.	Vice President, Health Policy	Tax↓	Class A Common Stock	4,100	$3.73	$15,293	181,584
2026-02-15	Grow Brian	Chief Commercial Officer	Tax↓	Class A Common Stock	10,559	$3.73	$39,385	639,562
2026-02-15	Grow Brian	Chief Commercial Officer	Tax↓	Class A Common Stock	3,346	$3.73	$12,481	669,031
2026-02-15	Francisco David	Chief Financial Officer	Tax↓	Class A Common Stock	13,769	$3.73	$51,358	506,647
2026-02-15	Montecalvo Antonio S.	Vice President, Health Policy	Tax↓	Class A Common Stock	3,523	$3.73	$13,141	178,061
2026-02-15	Freedman Lori	Chief Admin. and Legal Officer	Tax↓	Class A Common Stock	13,510	$3.73	$50,392	791,717
2026-02-15	Freedman Lori	Chief Admin. and Legal Officer	Tax↓	Class A Common Stock	4,043	$3.73	$15,080	842,416
2026-02-15	Cavorsi Robert	Vice President, Strategy	Tax↓	Class A Common Stock	5,442	$3.73	$20,299	171,507
2026-02-15	Bilbo Patrick	Chief Operating Officer	Tax↓	Class A Common Stock	5,114	$3.73	$19,075	943,948
2026-02-15	Cavorsi Robert	Vice President, Strategy	Tax↓	Class A Common Stock	5,549	$3.73	$20,698	176,949
2026-02-15	Francisco David	Chief Financial Officer	Tax↓	Class A Common Stock	13,369	$3.73	$49,866	520,416
2026-02-15	Montecalvo Antonio S.	Vice President, Health Policy	Tax↓	Class A Common Stock	1,389	$3.73	$5,181	195,291
2026-02-15	Cavorsi Robert	Vice President, Strategy	Tax↓	Class A Common Stock	6,667	$3.73	$24,868	182,498
2026-02-15	Freedman Lori	Chief Admin. and Legal Officer	Tax↓	Class A Common Stock	24,428	$3.73	$91,116	817,988
2026-02-15	Freedman Lori	Chief Admin. and Legal Officer	Tax↓	Class A Common Stock	12,761	$3.73	$47,599	805,227
2026-02-15	Bilbo Patrick	Chief Operating Officer	Tax↓	Class A Common Stock	15,352	$3.73	$57,263	884,648
2026-02-15	Grow Brian	Chief Commercial Officer	Tax↓	Class A Common Stock	11,144	$3.73	$41,567	628,418
2026-02-15	Gillheeney Gary S.	Director, President and CEO	Tax↓	Class A Common Stock	24,340	$3.73	$90,788	3,490,983
2026-02-15	Grow Brian	Chief Commercial Officer	Tax↓	Class A Common Stock	18,910	$3.73	$70,534	650,121
2026-02-15	Gillheeney Gary S.	Director, President and CEO	Tax↓	Class A Common Stock	78,646	$3.73	$293,350	3,412,337
2026-02-15	Francisco David	Chief Financial Officer	Tax↓	Class A Common Stock	3,898	$3.73	$14,540	555,197
2026-02-15	Montecalvo Antonio S.	Vice President, Health Policy	Tax↓	Class A Common Stock	9,607	$3.73	$35,834	185,684
2026-02-15	Francisco David	Chief Financial Officer	Tax↓	Class A Common Stock	21,412	$3.73	$79,867	533,785

Legend Buy — open-market purchase Sell — open-market sale ↑ Shares acquired ↓ Shares disposed (gift, conversion, tax…)

Showing 1–50 of 500 transactions

Key facts CIK 1661181 CUSIP 68621F102 13F (30d) 53 filings 41 filers Visit website Investor relations